(0.08%) 5 521.25 points
(0.14%) 39 899 points
(0.16%) 19 782 points
(-0.06%) $81.58
(0.68%) $2.83
(-0.28%) $2 337.90
(0.10%) $29.56
(0.49%) $1 006.70
(0.05%) $0.932
(-0.04%) $10.53
(0.02%) $0.788
(-0.84%) $87.25
-0.04% $ 25.52
Live Chart Being Loaded With Signals
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases...
Stats | |
---|---|
Dzisiejszy wolumen | 256 795 |
Średni wolumen | 182 685 |
Kapitalizacja rynkowa | 749.00M |
EPS | $-0.540 ( Q1 | 2024-05-09 ) |
Następna data zysków | ( $-0.500 ) 2024-08-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-14.92 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0590 (0.23%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-23 | Carr Edward | Buy | 60 000 | Stock Option (Right to Buy) |
2024-05-23 | Veness Adam M | Buy | 75 000 | Stock Option (Right to Buy) |
2024-05-23 | Randhawa Simrat | Buy | 100 000 | Stock Option (Right to Buy) |
2024-05-23 | Savitz Ryan | Buy | 100 000 | Stock Option (Right to Buy) |
2024-05-23 | Garcia Marino | Buy | 243 000 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
98.09 |
Last 29 transactions |
Buy: 6 689 948 | Sell: 58 857 |
Wolumen Korelacja
Dianthus Therapeutics, Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Dianthus Therapeutics, Korelacja - Waluta/Towar
Dianthus Therapeutics, Finanse
Annual | 2023 |
Przychody: | $2.83M |
Zysk brutto: | $2.47M (87.44 %) |
EPS: | $-8.45 |
FY | 2023 |
Przychody: | $2.83M |
Zysk brutto: | $2.47M (87.44 %) |
EPS: | $-8.45 |
FY | 2022 |
Przychody: | $6.42M |
Zysk brutto: | $6.27M (97.71 %) |
EPS: | $-32.57 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Dianthus Therapeutics,
Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej